Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Share-based Compensation (2022 - 2025)

Coeptis Therapeutics Holdings has reported Share-based Compensation over the past 4 years, most recently at $870.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $870.0 for Q4 2025, down 99.83% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 24.57% YoY), and the annual figure for FY2025 was $1.2 million, down 8.54%.
  • Share-based Compensation for Q4 2025 was $870.0 at Coeptis Therapeutics Holdings, down from $213035.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for COEPW hit a ceiling of $3.5 million in Q1 2022 and a floor of $870.0 in Q4 2025.
  • Median Share-based Compensation over the past 4 years was $202028.5 (2025), compared with a mean of $719097.1.
  • Peak annual rise in Share-based Compensation hit 516.92% in 2025, while the deepest fall reached 99.83% in 2025.
  • Coeptis Therapeutics Holdings' Share-based Compensation stood at $1.4 million in 2022, then tumbled by 91.1% to $128510.0 in 2023, then skyrocketed by 307.7% to $523929.0 in 2024, then plummeted by 99.83% to $870.0 in 2025.
  • The last three reported values for Share-based Compensation were $870.0 (Q4 2025), $213035.0 (Q3 2025), and $191022.0 (Q2 2025) per Business Quant data.